Summary
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves
ARS Pharmaceuticals is now focused on scaling Neffy. This is their needle-free epinephrine spray for severe allergic reactions, and it's also core to my bull case on SPRY. Recently, we've seen SPRY double down on CVS Caremark, Medicaid, retail affordability, and a larger sales force to improve Neffy's access by 2H2026. Neffy is already generating commercial revenue, and the next test for my bull case is whether repeat sales grow as access improves.
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals Q1 Earnings Call Highlights
ARS Pharmaceuticals NASDAQ: SPRY reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy, its needle-free epinephrine treatment for allergic reactions including anaphylaxis.
Ars Pharmaceuticals Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 400 | $5,800 | $2,918.36 | -$2,881.64 | -49.68% |
| CE Curtis Ellergodt Rothschild Investment LLC | 16 | $279.18 | $116.73 | -$162.45 | -58.19% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 92,875 | $1.26M | $676,705.82 | -$584,542.56 | -46.35% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,870 | $15,016.1 | $13,548.52 | -$1,467.58 | -9.77% |
 Daniel Loeb | 1M | $10.04M | $7.29M | -$2.76M | -27.45% |
Ars Pharmaceuticals Inc (SPRY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ars Pharmaceuticals Inc ever had a stock split?
Ars Pharmaceuticals Inc Profile
| Biotechnology Industry | Healthcare Sector | Richard E. Lowenthal CEO | NASDAQ (NMS) Exchange | 82835W108 CUSIP |
| US Country | 163 Employees | - Last Dividend | - Last Split | 4 Dec 2020 IPO Date |
Overview
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for severe allergic reactions. Established in 2015 and based in San Diego, California, the company is committed to improving the care and protection for patients experiencing life-threatening allergic reactions, also known as anaphylaxis. ARS Pharmaceuticals aims to serve a broad audience, including healthcare professionals, patients, and caregivers, by providing advanced, patient-friendly solutions for emergency situations.
Products and Services
neffy: The flagship product under development by ARS Pharmaceuticals, Inc. is neffy, a needle-free, intranasal epinephrine nasal spray designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Unlike traditional epinephrine auto-injectors, neffy offers a non-invasive, low-dose alternative that could transform the way severe allergic reactions are treated. The innovative nasal spray form aims to make administration less intimidating and more accessible in critical moments, thereby potentially increasing the likelihood of timely and effective treatment.
